Literature DB >> 30855706

All-cause hospitalizations in multiple sclerosis patients.

C Maia1, A Costa1,2, P Abreu2, M J Sa1,3.   

Abstract

INTRODUCTION: There is poor knowledge on current hospitalizations in the multiple sclerosis (MS) population. The purpose of this study was to determine hospitalization causes and outcomes in a MS hospital-based cohort. PATIENTS AND METHODS: A retrospective chart review was performed on all patients admitted at our centre between August, 2009 and July, 2015, excluding those with no previous established diagnosis.
RESULTS: 308 hospitalizations were included, representing a total of 155 patients (female, 67.5%). Median age at hospitalizations was 47 years, with median disease duration of 12 years. The most common overall reason for hospitalization was infectious diseases (22.1%), followed by MS relapses (12.7%) and neurogenic bladder (11%). The median length of hospitalization for all patients was 5 days and the progressive subtype of MS had longer lengths of hospitalization than the relapsing-remitting MS. Intensive care unit admission occurred in 23 cases (7.5%) and were associated with increased mortality and length of hospitalization. Of the 308 hospitalizations, 9 (2.9%) resulted in death.
CONCLUSION: Infections are the most common cause of hospitalizations in our study, although MS relapses or complications related to MS continue to be significant causes of morbidity. Almost 8% of all MS hospitalizations required intensive care unit admission and these were related to longer admission lengths and higher death rates.

Entities:  

Mesh:

Year:  2019        PMID: 30855706     DOI: 10.33588/rn.6806.2018281

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  3 in total

1.  Effectiveness of Dimethyl Fumarate in Real-World Clinical Practice and Strategy to Minimize Adverse Effects and Use of Healthcare Resources.

Authors:  Ana Rodríguez-Regal; Laura Ramos-Rúa; Luis Anibarro-García; Ana María Lopez Real; María Del Campo Amigo-Jorrín
Journal:  Patient Prefer Adherence       Date:  2021-01-29       Impact factor: 2.711

2.  Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.

Authors:  Guilherme Silva Julian; Ricardo Papaléo Rosim; Estela Cristina Carneseca; Jéssica Rigolon
Journal:  PLoS One       Date:  2020-03-02       Impact factor: 3.240

3.  Risk and outcomes of COVID-19 in patients with multiple sclerosis.

Authors:  Irene Moreno-Torres; Virginia Meca Lallana; Lucienne Costa-Frossard; Celia Oreja-Guevara; Clara Aguirre; Elda María Alba Suárez; Mayra Gómez Moreno; Laura Borrega Canelo; Julia Sabín Muñoz; Yolanda Aladro; Alba Cárcamo; Elena Rodríguez García; Juan Pablo Cuello; Enric Monreal; Susana Sainz de la Maza; Fernando Pérez Parra; Francisco Valenzuela Rojas; Carlos López de Silanes de Miguel; Ignacio Casanova; Maria Luisa Martínez Gines; Rosario Blasco; Aida Orviz García; Luisa María Villar-Guimerans; Guillermo Fernández-Dono; Víctor Elvira; Carmen Santiuste; Mercedes Espiño; José Manuel García Domínguez
Journal:  Eur J Neurol       Date:  2021-07-18       Impact factor: 6.288

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.